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Abstract
Preclinical disease models play an important role in the establishment of new treatment paradigms, identification of
biomarkers and assessment of drug efficacy and safety. However, the accuracy of these models in context of the human
disease are sometimes questioned, e.g. due to trials failing to confirm efficacy in humans. We suggest that one reason
behind this gap in predictability may relate to how the preclinical data is analyzed and interpreted. In the present paper, we
introduce a holistic approach to analyze and illustrate data in context of one of the most commonly used colitis models, i.e.
the mouse dextran sulphate sodium (DSS) colitis model. Diseased mice were followed over time along disease progression
and by use of tool pharmacological compounds activating nuclear hormone receptors, respectively. A new multivariate
statistics approach was applied including principal component analysis (PCA) with treatment prediction subsequent to
establishing the principal component analysis model. Thus, several studies could be overlaid and compared to each other in
a new, comprehensive and holistic way. This method, named mouse colitis global property screening, appears applicable
not only to any animal modelling series of studies but also to human clinical studies. The prerequisites for the study set up
and calculations are delineated and examples of new learnings from the global property screening will be presented.
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Introduction
Inflammatory Bowel Disease (IBD), Crohn’s disease (CD) and
ulcerative colitis (UC), are multifactorial, complex, lifelong diseases
with a broad spectrum of manifestations. The pathophysiology of
IBD is still unclear but it is well acknowledged that multiple
factors, including genetic, environmental and immunological,
contribute to the occurrence and perpetuation of the disease.
Furthermore, the patients on occasion also present with extrain-
testinal manifestations, such as cholangitis, uveitis, peri-anal and
oral lesions. The disease severity is quantified by grading
symptoms, which are then compiled in a univariate fashion to
generate disease activity scores, such as the Crohn’s disease activity
index (CDAI).
Evaluating the outcome of new drugs in a clinical study is
traditionally performed by statistical univariate methods created to
discover statistically significant improvements for the treated
patient group, in an unbiased way. However, univariate methods
need high object inclusion numbers to meet their significance
dependency and, in addition, some correlations are of truly
multivariate nature [1]. In terms of complex diseases such as IBD,
there is also a risk of overseeing clinically meaningful treatment
effects. Such treatment effects may be diluted and masked by
unrelated phenomena that are involved in the score, but not in the
targeted pathophysiology. On one hand, these approaches are
obviously required for drug development, both from ethical and
business aspects and the regulatory authorities delineate stringent
guidelines (see FDA guidelines), which the industry follows for
good reasons. The above perspective relates mainly to the later
development phase, i.e. clinical phase III studies, Research and
early development studies, on the other hand, could benefit from
parallel approaches, frontloading biological or physiological
relevance versus statistical significance. Several studies [2,3,4]
have indicated that multivariate analyses provide more in depth
knowledge than significance test statistics on the physiology and at
the systems biology level, and could therefore be applied to the
study designs. Such holistic methods can for instance describe how
individual animals alter their physiological pattern when they
develop disease or when they are subjected to pharmacological
treatment.
In terms of preclinical models for IBD, more than fifty models
have been described including genetically modified, chemically
induced, adoptive transfer of T cells and also few spontaneous
models (reviewed in [5,6]). It should be noted that none of these
models fully represent any form of human IBD. Rather, they can
be viewed upon as mechanistic models illustrating different
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gastrointestinal tract. As such, the models have contributed greatly
to our current understanding of the underlying mechanisms of
gastrointestinal inflammation and disease pathogenesis. However,
the complexity of gastrointestinal inflammation is seldom illus-
trated in these studies. Rather, there is a bias towards symptom
scoring that are compiled into univariate composite indices.
Similar to the human situation [7], these composite disease activity
indices may not be informative for the severity of the local
inflammation, and may therefore not be optimal endpoints for
understanding the underlying mechanisms behind the disease.
For both ethical and scientific reasons it is always important to
seek new ways to make the best use of any sacrificed animal, which
will lead to higher accuracy in ensuing clinical studies [8]. In line
with this thought we, by the current paper, want to present a new
way towards a holistic and robust modelling of animal data, as
exemplified on the murine dextran sodium sulphate (DSS) model
of colitis. This has been achieved by a global property screening
(GPS) approach, using a new way to set up data matrices for
principal component analyses (PCA), applied to the characteriza-
tion of the mouse model per se, but also to pharmacological
treatments with small molecules.
Results
The present study includes two independent series of experi-
ments using DSS-induced colitis in mice and thus two ways of
using multivariate modelling in experimental IBD. The first series
represents a description of the disease process over time in two
mouse strains and the second series how one of the mouse strains
respond to treatments with new chemical entities. The PCA
models were calculated by inclusion of healthy control mice in
combination with DSS-treated and DSS-treated plus placebo-
treated animals. The animals undertaking any intervention, e.g.
drug administration, were not used for building the model, but
subsequently predicted into the scores space using the established
PCA model.
Multivariate modelling of the disease dynamics in two
genetic backgrounds
The first validation data set included DSS-treated C57BL/6 as
well as BALB/c mice and the resulting PCA model provided
models including 3 principal components. The mouse strain
comparison between C57BL/6 versus BALB/c is depicted in
Figure 1, previously shown to behave differently following
exposure to DSS [9]. Indeed, the two strains behaved differently
after the DSS challenge. This was observed by inspection of the
individual animal positioning in the PCA scores plot. The PCA
scores are generated by estimation of the object inter-related
positioning in a scatter space comprising all collected biomarker
data. The method implements each biomarker data as an
individual and uniquely directed axis. In the example shown in
Figure 1, 21 different biomarkers were assessed, thus generating 21
uniquely directed axes. Thereafter, the PCA least squares
procedure was initiated, including the estimation of new vector
dimensions adhering to minimized sum of squared distance from
each data point to the generated vector, and thus the first PC is
generated. In cases when the model needs more than a one-
dimensional structure, a second and third and etc., component can
be generated using the residual data (i.e. after removal of the data
supporting the previously generated component). The validation
for PCA model complexity was in the present study estimated by
the cross-validation procedure as described in material and
methods. Analysis of the present dataset yielded four significant
PCs by the SIMCA P+ software. However, the fourth component
explained less that 7% of the total data variance and comprised a
negative contribution to Q
2 (i.e. the predictivity as assessed by
cross validation) and was therefore removed. The remaining three
PCs explained 73% (i.e. R2=0.732 for the X matrix) of the data
with Q
2=0.47. The model scores, i.e. individual animal sample
data scores, illustrating their time resolved reaction to the DSS
treatment as assessed by biomarkers, are shown in Figure 1.
Evidently both strains were clustering together at day 0, i.e. all
being healthy mice, after which the strain related property path
diverted, which thus illustrated a tangible way towards mouse
strain dependence to DSS response. Both strains revealed
overlapping disease profiles throughout the initial week (d7).
However, during the recovery phase the BALB/c mice moved, in
the PCA projection scores system, in a close to inverse direction
compared to the disease direction. After one week of recovery,
these animals were apparently healthy and their individual
position in the 3-dimensional score space were overlapping with
that of healthy control BALB/c mice, illustrating complete
recovery. C57BL/6 mice, on the other hand, did not recover
towards a healthy phenotype, as seen in the PCA scores plot
(Figure 1). Instead, they ended up in an orthogonal direction
compared to the trajectory towards the healthy profile of the
controls, but still different from the initial state induced by acute
DSS-treatment, illustrating the chronic inflammation they suffered
from.
In parallel, the influence from the primary biomarker variable
correlation pattern on the property paths in the DSS experiment
was inspected. This is achieved by use of the PCA inherent
calculation of loadings, which are obtained by the assessment of
the space angle between the direction of the original biomarker co-
ordinate axis and the resulting PCs, respectively (PC1, PC2 and
PC3 in the present example). A small space angle between a PC
and a biomarker original axis indicates high correlation to the
tested PC, and vice versa. Indeed the cosine of the obtained angle
coincides with the correlation coefficient between the two axes.
These estimates are called loadings (i.e. biomarker loadings in the
present study), which are highly instrumental for entailing
interpretation of observed individual animal trajectories and strain
clustering seen in the PCA of data from the DSS induced colitis
model (Figure 1).
Thus, we can conclude that the transition from health to acute
disease (day 0 to 7) was characterised by the presence of blood in
faeces and decreased biomarker loadings for colon levels of PGE2
in both BALB/c and C57BL/6 mice. In C57BL/6 mice, the
transition from day 7 to 12 was characterised by high diarrhoea
scores, increased weight loss, increased macroscopical signs of
colitis and peak colon levels of IL-1b, CCL2, CXCL2/3 and
CCL4. From day 19 and further on, the colon biomarker loadings
for cytokine levels and macroscopical signs of colitis remained
high. In addition, there were increased levels of CXL10 and IFNc.
Also, these time points were characterised by increased spleen
weights and recovered body weights. Thus, for short term studies
(up to 7 days) the two strains behave similarly and appeared
equally relevant for drug intervention studies, whereas for
chronicity studies the C57BL/6 mice should be used.
Evaluation of new chemical compounds using PCA
modeling
By pharmacological intervention we illustrate how the present
approach can be used in drug discovery. In this example, a defined
DSS-challenged mouse strain (BALB/c) was assessed for inflam-
matory biomarkers and other endpoints measured after treatment
with three different nuclear hormone receptor agonists (i.e. LXR,
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been shown to possess anti-inflammatory action, possibly via
mechanisms involving sequestration of and/or competition for
NF-kB cofactors [10,11].
First, a PCA-model was established using DSS- and placebo-
treated and healthy control mice, respectively, with the aim to
predict the data from animals receiving an additional compound
treatment. This is possible for any PCA model given that the same
variables, i.e. colitis biomarkers in the present study, are measured
coherently. The data alignment aspect is depicted in Figure 2 and
such prediction is straight-forward once a PCA model has been
created. The expected advantages from this approach relates to
standardization. Firstly, we provide a basic model that does not
change in scale, biomarker loading correlation pattern towards the
model PCs, or any other model property [12]. Secondly, when the
PCA model is used for prediction of a pharmacological compound
in treated animals (with or without DSS-pre-treatment) one can
assess the cohort clustering and interpret their systems pharma-
cology positioning via the scores plot as compared to the healthy
and DSS-treated cohort distributions (see Figure 3). However, in
this step it is of outmost importance over time to include model
animal objects to reveal any drift in the healthy and DSS treated
animal clustering, be it for animal phenotype due to e.g. health
status or response to DSS etc, or for drift in the analytical
measures settings (data not shown). Thirdly, over time it is possible
to combine any number of treatments and any comparison
combination, including reference and tool compound treatments,
for drug target and pharmacological mechanism investigation. By
using the PCA prediction mode for new samples, i.e. predicting
treated animal property positions into the initial model including
the sample data from healthy and diseased animals, a robust
model that facilitates interpretation between treatments over time
is provided.
The resulting systems pharmacology model on the present study
is illustrated in Figure 3A, comprising 2 significant principal
components. The reason for the lower model complexity
compared to the previous example, where two mouse strains with
DSS colitis were validated, was the restricted time used for the
pharmacological intervention, i.e. 7 days, and thus the modelling
of the ‘‘chronic’’ phase observed in C57BL/6 mice was omitted.
Figure 1. Multivariate projection of DSS-colitis development in BALB/c (Blue indicators, B) and C57BL/6 (Red indicators, C) mice.
Each cube represents an individual animal. The number next to the cubes indicates the number of days since the initiation of DSS-treatment (from
day 0 to day 40). Data were generated using a three-component principal component analysis (i.e. t1–t3 are plotted) based on the assessed variables
according to Materials and Methods. Arrows indicate disease progression in C57BL/6 mice.
doi:10.1371/journal.pone.0030005.g001
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model by prediction, illustrating the efficacies of three different
nuclear hormone receptor agonists (see Figure 2 and Figure 3B).
The biomarker and endpoint correlation pattern is depicted in
Figure 3C. Figures 3A and B show the model based on healthy
and vehicle-treated diseased mice. As shown in Figure 3A, mouse
V3, V10, V17, V19 and V23 responded poorly to the DSS
treatment (‘‘low responders’’), whereas the rest were classified as
‘‘diseased’’, but not ‘‘high responders’’. From the biomarker
loadings (see Figure 3C), it was evident that all parameters except
adiponectin and liver weight, were described by the first principal
component, and this component was also what discriminated
healthy from diseased mice. When the compound-treated animals
were predicted into the model, it showed that treatment with the
three NHR agonists generated three distinct patterns. Mice treated
with the PPARc agonist clustered towards the left-hand side along
principal component 1 in the scores plot (i.e. negative scores, see
Figure 3B), which represents higher plasma levels of haptoglobin
(acute phase protein) and local markers of inflammation.
Compared to PPARc treated mice, LXR-treated mice comprised
somewhat lower principal component 1 scores, demonstrating
better anti-inflammatory efficacy. Finally, the PPARa-treated
mice demonstrate the highest degree of disease amelioration of the
three groups. However, the PPARa-treated mice also had low
scores in the second component, due to high level biomarker
loadings for liver weights in combination with low for plasma levels
of adiponectin. From the loadings plot one can also conclude that
the increased liver weight, which is a well-known effect by PPARa
agonists [13], as well as the increased plasma levels of adiponectin,
occurred independently from the anti-inflammatory action. Such
interpretation can be drawn since adiponectin (and liver weight)
loadings mapped orthogonally against the inflammatory biomark-
ers in the loadings plot (Figure 3C). Finding such uncoupled
phenomena by orthogonal distributions of biomarker loadings
illustrates an inherent property of multivariate analysis and
unfolding the same pattern by univariate data analysis is less
obvious. Rather, univariate analyses would, somewhat mislead-
ingly, have suggested that liver weight increases occurs along with
anti-inflammatory action (as illustrated in Figure 4).
Discussion
In the present paper, we have exemplified how multivariate
analysis can be used to illustrate complex disease processes in a
holistic manner and also document effects of pharmacological
interventions on experimental colitis.
One hurdle for using PCA-analysis in inter-experimental
comparisons is the mathematical rotation along principal compo-
nents (i.e. mirror images of t-scores) that can occur. Although a
mirror image of the t score is mathematically as valid as the
original t score, it precludes comparison with data based on the
original t score However, by using a holistic global property
screening (GPS) approach with fixed principal components as
presented herein, such rotations along principal components are
avoided. Thus, pharmacological models (Figure 1) and compound
treatment (Figure 3) can be compared to each other without scores
and loadings scale alterations or rotations. These procedures
standardize the interpretations over time of sequential analyses
and contribute to holistic knowledge gain, which is the core
property of GPS modelling concept [12]. Thus, it provides a
background template system, in which instilled perturbations, e.g.
pharmacological compounds, strain shifts including mutations,
and housekeeping studies for robustness testing, etc, can be
monitored. In other words, the GPS will help any user to simplify
any comparisons of phenotypic perturbation, be it from disease
model aspects or compound distribution for disease amelioration
purposes, as long as the data structure complies with each other’s
format regarding measurements of biomarkers and other charac-
terizing variables (see Figure 2).
Extrapolating the surplus findings provided by the GPS
approach in the present study makes it tempting to conjecture
that similar modelling of human clinical phase II data [14] could
provide new important and ethically relevant insights by global
comparability. This would add to Chalmers’ [15] well formulated
arguments regarding the importance of transparency of clinical
data for ensuing translational information exchange. Regarding
the possible translation by GPS-modelling to clinical data one
must keep in mind the importance of maintained ethical
considerations and that study design must be strictly regulated.
However, we envision that parallel application of multivariate
methodology could lead to synergistic learnings in clinical data
analysis, for instance by contextualisation of biomarker data. First,
PCA is an excellent tool to find the unforeseen. Unlike traditional
data univariate analysis, PCA is not hypothesis-driven, but a tool
to discover correlations in an unbiased manner. Second, the
holistic principles of PCA will identify synergistic processes that
often occur in biological systems, which would not necessarily be
unveiled using traditional null-hypothesis based, univariate data-
analysis. Along the same line, the PCA will also readily pinpoint
parallel, independent processes that may occur in biological
systems, such as the effect of PPARa-agonism on liver weight vs.
intestinal inflammation as shown in the present paper. This means
that PCA could provide useful knowledge and be a means to deal
with the publication bias in which inconclusive or negative data
are not published [8,15]. There are of course limitations with GPS.
One considerable hurdle during implementation relates to the
relatively abstract nature of the multivariate space. It can be
Figure 2. Schematic overview of matrix relation for the GPS
calculations. The PCA model include healthy as well as placebo
treated DSS-exposed mice. The distribution of these mice in the PCA
model is shown in Figure 3A. The mice positioned into the PCA-model
were treated with DSS- together with a LXR-agonist, PPARa-agonist or
PPARc-agonist. The positions of these mice are shown in Figure 3B.
doi:10.1371/journal.pone.0030005.g002
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to be un-structured, suddenly provide useful information and
therefore should not be discarded. Secondly, the GPS-method is
constrained to a pre-selected finite set of endpoints. As soon as one,
or several variables are excluded or new variables are added into
the data matrix (such as newly identified biomarkers), there is a
risk of skewing and thereby limited predictive value of the model.
In conclusion, GPS modelling provides a good overview of data
from complex measurements of biological systems, including
holistic views on population distributions, definition of outlier
individuals, and entailing model interpretation abilities to pinpoint
serendipitous observanda, not the least by use of the additional
GPS properties. This includes a potential for treatment stratifica-
tion support [16,17] due to the straight forward pattern
recognition properties via scores and biomarker loadings inter-
pretation with opportunities for generation of multivariate
stratification criteria. Finally, given that both animals and clinical
patients undergo intervention with the same compound, a data
structure with inherent properties for concatenation between
animal models and human disease might come closer in sight [4].
Materials and Methods
Ethics statement
The procedures described herein were approved by the local
animal ethics committee in Gothenburg, Sweden (approvals 220/
2002 and 62/2004). The mice were housed in an environment
enriched with chewing sticks, nest material and egg cartons.
During the experiment, the general condition of the mice was
monitored at least twice daily and individuals that displayed a
significantly impaired state of health, i.e. were inactive, had ruffled
fur or were unwilling to seek chow and water, were euthanized.
Mice, induction of colitis and tissue sampling
Specific pathogen-free female BALB/cOlaHsD or C57BL/
6OlaHsD mice obtained from Harlan (Netherlands) were used.
The mice were housed in groups of up to 8 mice per cage and
acclimatised for two weeks before the start of the experiment. The
mice were fed R3 pellet chow (Lactamin) and tap water ad lib.
Addition of DSS to the drinking water was used to induce colitis as
previously described [9,18]. Briefly, a 3% (w/v) solution of 45 kD
DSS (TdB consultancy, Uppsala, Sweden) was given for 5 days to
C57BL/6 mice or 5% DSS for the indicated number of days to
BALB/c mice. Fresh DSS was prepared daily to avoid bacterial
growth in the solution. Healthy controls received normal tap
water. Throughout the study, mice were monitored for symptoms
(body weight, hunched posture, piloerection, and blood in the
anus). During termination of the study, blood was taken by
retroorbital puncture under isofluran anaesthesia and collected in
EDTA-containing tubes, after which the mice were killed by
cervical dislocation. The blood samples were centrifuged
3000 rpm for 10 minutes at 4uC, and plasma aliquoted and
frozen at 280uC. The colon was dissected out, cut open, carefully
rinsed and scored for macroscopical signs of inflammation
(rigidity, thickness, ulcerations and oedema), yielding a maximal
score of 10 [19], after which the distal 3 cm was divided and either
frozen in liquid nitrogen (for cytokine analysis) or fixed in Zinc
formaldehyde (for histology analyses) [9].
Biomarker analyses
As a marker for systemic inflammation, the plasma levels of the
acute phase protein haptoglobin were measured using a Cobas Bio
centrifugal analyser with a haptoglobin reagent kit (TP801, Tridelta
development). In the strain comparison shown in Figure 1, plasma
was also analysed for the levels of IL-6, IL-12p40, TNF and
CXCL1/KC using the xMAP technology developed by Luminex
Corporation (Austin, Texas) as previously described [9].
To analyse local levels of inflammatory mediators, colon tissue
was homogenised in PBS (Gibco, Invitrogen Corp UK) supple-
mented with 10% foetal calf serum and a protease inhibitor
cocktail (Complete Mini, Roche Molecular Biochemicals), using a
Homogenizer (Ultra Turrax T8, Tamro, Sweden). The homog-
enised material was centrifuged, 18000 rpm for 10 min, at +4uC,
after which the supernatant was aliquoted and frozen at 280uC.
To generate the data shown in Figure 1, the colonic levels of IL-
1b, IL-12p40, IL-18, IFNc, CXCL1/mouse KC, CXCL2/3-MIP-
2, CXCL9/MIG, CXCL10/IP-10, CCL2/mouse JE/MCP-1,
CCL4/MIP-1b, CCL5/RANTES and PGE2 were determined by
ELISA according to the manufacturer’s instructions (R&D
Systems, UK and Cayman Chemical Company, MI (PGE2)). All
cytokine data are expressed as pg/100 mg colon tissue.
Treatment with nuclear hormone receptor agonists
BALB/c mice were exposed to 5% DSS in the drinking water
for 6 days. The mice were orally treated by gavage with either
Figure 4. Univariate analysis of the effect of PPARa-agonist
treatment on macroscopic colon scores (A) and liver weights
(B). Macroscopic colon scores were assessed as described in material
and methods. * p=0.02; *** p,0.001.
doi:10.1371/journal.pone.0030005.g004
Figure 3. Evaluation of new chemical compounds using PCA modelling. A. Mouse colitis GPS model as generated from healthy control mice
(open triangles) and placebo treated DSS-exposed mice (closed triangles) (see upper part of matrix in Figure 1). Based on the distance from the
healthy control along the t(1) axis (i.e. the severity of the colitis) the mice are either classified as low responders, diseased or high responders.
B. Mouse colitis GPS model including predictions for mice given nuclear hormone receptor agonists (dosing regimen as described in Materials and
Methods), with receptor specificity as indicated (LXR (closed diamonds), PPARa (stars) and PPARc (open diamonds)). Based on the position along the
tPS(1) axis relative to the placebo-treated animals shown in Figure 3A, the effect of the treatment on the disease is either classified as ameliorated,n o
effect or aggravated. C. Individual variable correlation structure (i.e., loadings p1 versus p2 for PCA generated for objects in A) superimposable for
interpretation of clustering in Figure 3A and B. The variables were plasma levels of haptoglobin, adiponectin and triglycerides (TG), colon levels of
MCP1, KC, IL-6 and IL-12p40, colon weight, body weight, liver weight, colon length and macroscopic colon score. For example the PPARa-agonist
treated animals in (B) are clustering in the lower end of principal component 2, due to high liver weight (and low adiponectin levels) and low
principal component 1 due to reduced colitis.
doi:10.1371/journal.pone.0030005.g003
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1 mmol/kg of the peroxisome proliferation activating receptor
(PPAR)a-agonist AZ-63233 or 30 mmol/kg of the PPARc-agonist
AZ-15188, each group containing 12 mice. The compounds were
suspended in hydroxypropylmethyl cellulose (Kleptose, Roquette)
and administered at 10 ml/kg bodyweight. All treatments were
performed once daily, starting one day before the addition of DSS
and continued until the day before the termination of the
experiment. Biomarkers in these experiments were colon levels
of cytokines (IL-12p40, IL-6, MCP1 and KC determined by
xMAP technology), and plasma levels of haptoglobin, triglycerides
(Diagnostics GMBH, Mannheim Germany) and adiponectin
(Linco Research Inc Missouri, USA). In addition, colon and liver
weights were recorded and colons macroscopically scored for
inflammation as described above.
Data analysis and statistics
Data analyses were performed using PCA as implemented in
the SIMCA-P software v. 11.0 and 12.0 (Umetrics, Umea,
Sweden, see www.umetrics.com). PCA bilinearise a data matrix
into scores and loading vectors, representing the objects and
variables respectively [20]. Each endpoint (i.e. variable with its
related loading) was, through-out all principal component analyses
in the present study, given equal leverage to the ensuing model by
the unit variance normalization procedure (according to the
SIMCA P+ software default implementation) First the variance
(i.e. the squared standard deviation SD) was calculated for each
biomarker’s data column and thereafter each individual datum
value was divided by its biomarker variance value rendering a unit
variance scaling. Thus the full data-set became re-scaled to
comprise the standard deviation equal to 1, for each normalized
biomarker data column, which in practise means an a priori equal
chance of influence for each included biomarker measure
independent on the initial raw data scale.
The relevant number of principal components (PC) was decided
from the R
2, Eigen value and loading structure, related to the
respective component. Furthermore, cross-validation [21] was
used as an additional measure for model judgement of proper
model complexity.
Statistical significance shown in Figure 4 was calculated using
the Mann-Whitney U-test in the software GraphPad Prism 4.0.
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